The ICC has a more nuanced approach, sometimes excluding TP53-mutated cases from lower-risk categories, such as MDS with low blast count (MDS-LB), particularly if these mutations are associated with complex karyotypes. The gene discussed is TP53; the disease is myelodysplastic syndrome.